Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

Human Gene Therapy

Volumn 10, Issue 12, 1999, Pages 1993-2003

  Hamstra, Daniel A ^a   Rice, David J ^a   Fahmy, Samer ^a   Ross, Brian D ^a   Rehemtulla, Alnawaz ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; CYTOSINE DEAMINASE; DRUG METABOLITE; FLUCYTOSINE; FLUOROURACIL; PRODRUG;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME SUBSTRATE COMPLEX; ENZYME THERAPY; GENE THERAPY; HEAD CANCER; MOUSE; NECK CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RETROVIRUS INFECTION; SACCHAROMYCES CEREVISIAE; TUMOR REGRESSION;

ANIMALS; ANTIFUNGAL AGENTS; CARCINOMA, SQUAMOUS CELL; COS CELLS; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; MICE; NUCLEOSIDE DEAMINASES; PRODRUGS; RETROVIRIDAE; SACCHAROMYCES CEREVISIAE; TUMOR CELLS, CULTURED;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; SACCHAROMYCES CEREVISIAE; UNIDENTIFIED RETROVIRUS;

EID: 0033543123     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017356     Document Type: Article

References (36)

1. BENNETT, J.E. (1996). Antimicrobial agents: Antifungal agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, and A.G. Gilman, eds. (McGraw-Hill, New York) pp. 1175-1190.
2. CHABNER, B.A., ALLEGRA, C.J., CURT, G.A., and CALABRESI, P. (1996). Antineoplastic Agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, and A.G. Gilman, eds. (McGraw-Hill, New York) pp. 1233-1287.
3. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256(5063), 1550-1552.
4. DIASIO, R., LAKINGS, D., and BENNETT, J. (1978). Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: Possible factor in 5-fluorocytosine toxicity. Antimicrob. Agents Chemother. 14(6), 903-908.
5. DINESMAN, A., HAUGHEY, B., GATES, G.A., AUFDEMORTE, T., and VON HOFF, D.D. (1990). Development of a new in vivo model for head and neck cancer. Otolaryngol. Head Neck Surg. 103(5), 766-774.
6. ERBS, P., EXINGER, F., and JUND, R. (1997). Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr. Genet. 31(1), 1-6.
7. FICK, J., BARKER, F.G., II, DAZIN, P., WESTPHALE, E.M., BEYER, E.C., and ISRAEL, M.A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. U.S.A. 92(24), 11071-11075.
8. CLICK, J.H., ZEHNGEBOT, L.M., and TAYLOR, S.G.T. (1980). Chemotherapy for squamous cell carcinoma of the head and neck: A progress report. Am. J. Otolaryngol. 1(4), 306-323.
9. HAMSTRA, D.A., and REHEMTULLA, A. (1999). Toward an enzyme/prodrug strategy for cancer gene therapy: Endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum. Gene Ther. 10(2), 235-248.
10. HAMSTRA, D.A., PAGÉ, M., MAYBAUM, J., and REHEMTULLA, A. (1999a). In review.
11. HAMSTRA, D.A., RICE, D.J., PU, A., OYEDIJO, D., ROSS, B.D., and REHEMTULLA, A. (1999b). Combined radiotherapy and enzyme/prodrug therapy for head and neck cancer in an orthotopic animal model. Rad. Res. (in press).
12. HANNA, N.N., MAUCERI, H.J., WAYNE, J.D., HALLAHAN, D.E., KUFE, D.W., and WEICHSELBAUM, R.R. (1997). Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57(19), 4205-4209.
13. HUBER, B.E., AUSTIN, E.A., GOOD, S.S., KNICK, V.C., TIBBELS, S., and RICHARDS, C.A. (1993). In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53 (19), 4619-4626.
14. HUBER, B.E., AUSTIN, E.A., RICHARDS, C.A., DAVIS, S.T., and GOOD, S.S. (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U.S.A. 91(17), 8302-8306.
15. KATSURAGI, T., SAKAI, T., MATSUMOTO, K., and TONOMURA, K. (1986). Cytosine deaminase from Escherichia coli-production, purification, and some characteristics. Agric. Biol. Chem. 50, 1721-1730.
16. KATSURAGI, T., SONODA, T., MATSUMOTO, K., SAKAI, T., and TONOMURA, K. (1989). Purification and some properties of cytosine deaminase from baker's yeast. Agric. Biol. Chem. 53, 1313-1319.
17. KHIL, M., KIM, J., MULLEN, C, KIM, S., and FREYTAG, S. (1996). Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine-deaminase gene. Clin. Cancer Res. 2, 53-57.
18. KIEVIT, E., BERSHAD, E., NG, E., SETHNA, P., DEV, I., LAWRENCE, T.S., and REHEMTULLA, A. (1999). Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 59(7), 1417-1421.
19. LAWRENCE, T.S. (1988). Reduction of doxorubicin cytotoxicity by ouabain: Correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res. 48(3), 725-730.
20. LAWRENCE, T.S., REHEMTULLA, A., NG, E.Y., WILSON, M., TROSKO, J.E., and STETSON, P.L. (1998). Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res. 58(12), 2588-2593.
21. MESNIL, M., PlCCOLI, C., TIRABY, G., WILLECKE, K., and YAMASAKI, H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. U.S.A. 93(5), 1831-1835.
22. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46(10), 5276-5281.
23. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82(4), 297-300.
24. MULLEN, C.A., COALE, M.M., LOWE, R., and BLAESE, R.M. (1994). Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54(6), 1503-1506.
25. NICULESCU-DUVAZ, I., SPOONER, R., MARAIS, R., and SPRINGER, C.J. (1998). Gene-directed enzyme prodrug therapy. Bioconj. Chem. 9(1), 4-22.
26. O'MALLEY, B.W., JR., COPE, K.A., JOHNSON, C.S., and SCHWARTZ, M.R. (1997a). A new immunocompetent murine model for oral cancer. Arch. Otolaryngol. Head Neck Surg. 123(1), 20-24.
27. O'MALLEY, B.W., JR., SEWELL, D.A., LI, D., KOSAl, K., CHEN, S.H., WOO, S.L., and DUAN, L. (1997b). The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. MoL. Endocrinol. 11(6), 667-673.
28. PEDERSON, L.C., BUCHSBAUM, D.J., VICKERS, S.M., KANCHARLA, S.R., MAYO, M.S., CURIEL, D.T., and STACKHOUSE, M.A. (1997). Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57(19), 4325-4332.
29. REHEMTULLA, A., and KAUFMAN, R.J. (1992). Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 79(9), 2349-2355.
30. RICHARDS, C.A., AUSTIN, E.A., and HUBER, B.E. (1995). Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6(7), 881-893.
31. ROGULSKI, K.R., KIM, J.H., KIM, S.H., and FREYTAG, S.O. (1997). Glioma cells tranduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 8(1), 73-85.
32. ROSS, B.D., ZHAO, Y.J., NEAL, E.R., STEGMAN, L.D., ERCOLANI, M., BEN-YOSEPH, O., and CHENEVERT, T.L. (1998). Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: An MRI study. Proc. Natl. Acad. Sci. U.S.A. 95(12), 7012-7017.
33. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S., and BOYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82(13), 1107-1112.
34. STEGMAN, L.D., REHEMTULLA, A., BEATTIE, B., KIEVIT, E., LAWRENCE, T.S., BLASBERG, R.G., TJUVAJEV, J.G., and ROSS, B.D. (1999). Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenographs in vivo with magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. (in press).
35. TRINH, Q.T., AUSTIN, E.A., MUURAY, D.M., KNICK, V.C., and HUBER, B.E. (1995). Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55(21), 4808-4812.
36. WYGODA, M.R., WILSON, M.R., DAVIS, M.A., TROSKO, J.E., REHEMTULLA, A., and LAWRENCE, T.S. (1997). Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan effect. Cancer Res. 57(9), 1699-1703.